Protein Therapeutics Market
Protein Therapeutics Market Forecasts to 2030 - Global Analysis By Product Type (Monoclonal Antibodies, Insulin, Fusion Proteins, Erythropoietin,, Interferon and Other Product Types), Function, Source, Route of Administration, Application, End User and By Geography
|
Years Covered |
2022-2030 |
|
Estimated Year Value (2024) |
US $717.6 MN |
|
Projected Year Value (2030) |
US $1386.5 MN |
|
CAGR (2024 - 2030) |
11.6% |
|
Regions Covered |
North America, Europe, Asia Pacific, South America, and Middle East & Africa |
|
Countries Covered |
US, Canada, Mexico, Germany, UK, Italy, France, Spain, Japan, China, India, Australia, New Zealand, South Korea, Rest of Asia Pacific, South America, Argentina, Brazil, Chile, Middle East & Africa, Saudi Arabia, UAE, Qatar, and South Africa |
|
Largest Market |
North America |
|
Highest Growing Market |
Asia Pacific |
According to Stratistics MRC, the Global Protein Therapeutics Market is accounted for $373.9 billion in 2024 and is expected to reach $600.0 billion by 2030 growing at a CAGR of 8.2% during the forecast period. Protein therapeutics are biologically active proteins used as treatments for various diseases. They can replace abnormal or deficient proteins, augment existing biological pathways, or provide new functions. Common types include monoclonal antibodies, enzymes, and hormones. These therapeutics are often genetically engineered to enhance their efficacy and stability, allowing for targeted therapies that minimize side effects. The development of protein therapeutics has revolutionized medicine, providing effective treatments for conditions such as cancer, autoimmune disorders, and genetic diseases13.
According to the World Health Organization (WHO), chronic diseases account for 71% of all deaths ly. Protein therapeutics are often used to treat these conditions, driving growth in the market.
Market Dynamics:
Driver:
Increasing prevalence of chronic diseases
The rising prevalence of chronic diseases, such as diabetes, cancer, and cardiovascular disorders, is significantly driving growth in the market. As these conditions become more common, the demand for targeted and effective treatment options increases. Protein therapeutics, known for their precision and ability to modify complex biological pathways, are increasingly favored for managing these diseases. This trend is further supported by advancements in biotechnology and personalized medicine, leading to innovative therapies.
Restraint:
Biosimilarity and bioequivalence concerns
Concerns regarding biosimilarity and bioequivalence significantly hinder the market. Uncertainties about whether biosimilars can match the efficacy and safety of reference products lead to reluctance among healthcare providers and patients to embrace these alternatives. Additionally, the complexity of regulatory requirements may delay the entry of cost-effective biosimilars, ultimately limiting patient access to more affordable treatments for chronic conditions and perpetuating high healthcare costs.
Opportunity:
Growing research and development investments
Growing investments in research and development are fueling advancements in the market, driving innovation and expanding treatment options. Pharmaceutical companies are increasingly allocating resources to explore novel protein-based therapies, targeting complex diseases such as cancer, autoimmune disorders, and rare genetic conditions. This surge in funding supports cutting-edge technologies like gene editing and protein engineering, enhancing the specificity and efficacy of therapeutic candidates.
Threat:
High development and manufacturing costs
High development and manufacturing costs are significant challenges in the market, often limiting accessibility and affordability. The complex processes required for designing, producing, and purifying protein-based therapies demand substantial financial investment and specialized expertise. These financial barriers may deter smaller companies from entering the market and can lead to higher prices for patients and healthcare systems, ultimately impacting the overall availability of innovative treatment options.
Covid-19 Impact:
The COVID-19 pandemic had a profound impact on the protein therapeutics market, accelerating the development of novel treatments and vaccines. Increased funding and collaboration among researchers and pharmaceutical companies led to rapid advancements in protein-based therapies, particularly in addressing viral infections and immune responses. However, the pandemic also disrupted supply chains and clinical trials, delaying some therapeutic developments.
The fusion proteins segment is projected to be the largest during the forecast period
The fusion proteins segment is projected to account for the largest market share during the projection period. These engineered proteins can improve targeting mechanisms, extend half-life, and modulate immune responses, making them valuable in treating various diseases, including cancer and autoimmune disorders. Advances in biotechnology have facilitated the development of novel fusion proteins, leading to innovative therapies that can outperform traditional treatments.
The cardiovascular diseases segment is expected to have the highest CAGR during the forecast period
The cardiovascular diseases segment is expected to have the highest CAGR during the extrapolated period. Innovative protein-based therapies, such as monoclonal antibodies and peptides, are being developed to target specific pathways involved in heart disease, hypertension, and cholesterol management. As research advances, the growing understanding of the molecular mechanisms underlying CVDs is expected to drive the development of more effective protein therapeutics, improving patient outcomes.
Region with largest share:
North America region is projected to account for the largest market share during the forecast period. The region benefits from significant investments in healthcare innovation and a favorable regulatory environment that accelerates the approval of new therapies. With a high prevalence of chronic diseases and increasing demand for targeted treatments, it is home to numerous pharmaceutical companies and research institutions pioneering advancements in protein-based therapies, ultimately enhancing patient care and expanding market growth.
Region with highest CAGR:
Asia Pacific is expected to register the highest growth rate over the forecast period driven by increasing incidence of chronic diseases, such as cancer, diabetes, and autoimmune disorders. Governments and private entities in many countries are investing more in healthcare infrastructure and access, which has created opportunities for the market. The region has witnessed significant advancements in biotechnology, enabling the development and production of complex protein therapeutics.
Key players in the market
Some of the key players in Protein Therapeutics market include Eli Lilly and Company, Merck & Co. Inc., Novo Nordisk A/S, Amgen Inc., Pfizer Inc., Baxter International Inc., Abbott Laboratories, Abbvie Inc., Johnson & Johnson, Sanofi, Takeda Pharmaceutical Company Limited, Bayer AG, Generex Biotechnology Corp., Teva Pharmaceutical Industries Ltd, AstraZeneca, BioNtech and Ractigen Therapeutics.
Key Developments:
In February 2024, BioNtech, a next-generation immunotherapy company, and Autolus, a clinical-stage biopharmaceutical company, announced the strategic collaboration for CAR-T Cell Therapy.
In January 2024, Ractigen Therapeutics, a leading clinical-stage pharmaceutical industry leader in charge of small activated RNA therapeutics, announced a strategic partnership with Utrecht University-affiliated University Medical Center. The collaboration strengthens the saRNA-based treatments for a spectrum of intractable neurodevelopmental disorders.
Product Types Covered:
• Monoclonal Antibodies
• Insulin
• Fusion Proteins
• Erythropoietin
• Interferon
• Other Product Types
Functions Covered:
• Replacement Therapy
• Stimulation Therapy
• Inhibition Therapy
• Neutralization Therapy
Sources Covered:
• Animal-Derived
• Microbial-Derived
• Plant-Derived
• Recombinant Sources
Route of Administrations Covered:
• Injectable
• Oral
• Transdermal
• Inhalation
Applications Covered:
• Oncology
• Autoimmune Disorders
• Infectious Diseases
• Metabolic Disorders
• Cardiovascular Diseases
• Neurological Disorders
• Other Applications
End Users Covered:
• Hospitals
• Pharmaceutical Companies
• Research Institutions
• Biotechnology Firms
• Other End Users
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 Application Analysis
3.8 End User Analysis
3.9 Emerging Markets
3.10 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Protein Therapeutics Market, By Product Type
5.1 Introduction
5.2 Monoclonal Antibodies
5.3 Insulin
5.4 Fusion Proteins
5.5 Erythropoietin
5.6 Interferon
5.7 Other Product Types
6 Global Protein Therapeutics Market, By Function
6.1 Introduction
6.2 Replacement Therapy
6.3 Stimulation Therapy
6.4 Inhibition Therapy
6.5 Neutralization Therapy
7 Global Protein Therapeutics Market, By Source
7.1 Introduction
7.2 Animal-Derived
7.3 Microbial-Derived
7.4 Plant-Derived
7.5 Recombinant Sources
8 Global Protein Therapeutics Market, By Route of Administration
8.1 Introduction
8.2 Injectable
8.2.1 Subcutaneous
8.2.2 Intravenous
8.2.3 Intramuscular
8.3 Oral
8.4 Transdermal
8.5 Inhalation
9 Global Protein Therapeutics Market, By Application
9.1 Introduction
9.2 Oncology
9.3 Autoimmune Disorders
9.4 Infectious Diseases
9.5 Metabolic Disorders
9.6 Cardiovascular Diseases
9.7 Neurological Disorders
9.8 Other Applications
10 Global Protein Therapeutics Market, By End User
10.1 Introduction
10.2 Hospitals
10.3 Pharmaceutical Companies
10.4 Research Institutions
10.5 Biotechnology Firms
10.6 Other End Users
11 Global Protein Therapeutics Market, By Geography
11.1 Introduction
11.2 North America
11.2.1 US
11.2.2 Canada
11.2.3 Mexico
11.3 Europe
11.3.1 Germany
11.3.2 UK
11.3.3 Italy
11.3.4 France
11.3.5 Spain
11.3.6 Rest of Europe
11.4 Asia Pacific
11.4.1 Japan
11.4.2 China
11.4.3 India
11.4.4 Australia
11.4.5 New Zealand
11.4.6 South Korea
11.4.7 Rest of Asia Pacific
11.5 South America
11.5.1 Argentina
11.5.2 Brazil
11.5.3 Chile
11.5.4 Rest of South America
11.6 Middle East & Africa
11.6.1 Saudi Arabia
11.6.2 UAE
11.6.3 Qatar
11.6.4 South Africa
11.6.5 Rest of Middle East & Africa
12 Key Developments
12.1 Agreements, Partnerships, Collaborations and Joint Ventures
12.2 Acquisitions & Mergers
12.3 New Product Launch
12.4 Expansions
12.5 Other Key Strategies
13 Company Profiling
13.1 Eli Lilly and Company
13.2 Merck & Co. Inc.
13.3 Novo Nordisk A/S
13.4 Amgen Inc.
13.5 Pfizer Inc.
13.6 Baxter International Inc.
13.7 Abbott Laboratories
13.8 Abbvie Inc.
13.9 Johnson & Johnson
13.10 Sanofi
13.11 Takeda Pharmaceutical Company Limited
13.12 Bayer AG
13.13 Generex Biotechnology Corp.
13.14 Teva Pharmaceutical Industries Ltd
13.15 AstraZeneca
13.16 BioNtech
13.17 Ractigen Therapeutics
List of Tables
1 Global Protein Therapeutics Market Outlook, By Region (2022-2030) ($MN)
2 Global Protein Therapeutics Market Outlook, By Product Type (2022-2030) ($MN)
3 Global Protein Therapeutics Market Outlook, By Monoclonal Antibodies (2022-2030) ($MN)
4 Global Protein Therapeutics Market Outlook, By Insulin (2022-2030) ($MN)
5 Global Protein Therapeutics Market Outlook, By Fusion Proteins (2022-2030) ($MN)
6 Global Protein Therapeutics Market Outlook, By Erythropoietin (2022-2030) ($MN)
7 Global Protein Therapeutics Market Outlook, By Interferon (2022-2030) ($MN)
8 Global Protein Therapeutics Market Outlook, By Other Product Types (2022-2030) ($MN)
9 Global Protein Therapeutics Market Outlook, By Function (2022-2030) ($MN)
10 Global Protein Therapeutics Market Outlook, By Replacement Therapy (2022-2030) ($MN)
11 Global Protein Therapeutics Market Outlook, By Stimulation Therapy (2022-2030) ($MN)
12 Global Protein Therapeutics Market Outlook, By Inhibition Therapy (2022-2030) ($MN)
13 Global Protein Therapeutics Market Outlook, By Neutralization Therapy (2022-2030) ($MN)
14 Global Protein Therapeutics Market Outlook, By Source (2022-2030) ($MN)
15 Global Protein Therapeutics Market Outlook, By Animal-Derived (2022-2030) ($MN)
16 Global Protein Therapeutics Market Outlook, By Microbial-Derived (2022-2030) ($MN)
17 Global Protein Therapeutics Market Outlook, By Plant-Derived (2022-2030) ($MN)
18 Global Protein Therapeutics Market Outlook, By Recombinant Sources (2022-2030) ($MN)
19 Global Protein Therapeutics Market Outlook, By Route of Administration (2022-2030) ($MN)
20 Global Protein Therapeutics Market Outlook, By Injectable (2022-2030) ($MN)
21 Global Protein Therapeutics Market Outlook, By Subcutaneous (2022-2030) ($MN)
22 Global Protein Therapeutics Market Outlook, By Intravenous (2022-2030) ($MN)
23 Global Protein Therapeutics Market Outlook, By Intramuscular (2022-2030) ($MN)
24 Global Protein Therapeutics Market Outlook, By Oral (2022-2030) ($MN)
25 Global Protein Therapeutics Market Outlook, By Transdermal (2022-2030) ($MN)
26 Global Protein Therapeutics Market Outlook, By Inhalation (2022-2030) ($MN)
27 Global Protein Therapeutics Market Outlook, By Application (2022-2030) ($MN)
28 Global Protein Therapeutics Market Outlook, By Oncology (2022-2030) ($MN)
29 Global Protein Therapeutics Market Outlook, By Autoimmune Disorders (2022-2030) ($MN)
30 Global Protein Therapeutics Market Outlook, By Infectious Diseases (2022-2030) ($MN)
31 Global Protein Therapeutics Market Outlook, By Metabolic Disorders (2022-2030) ($MN)
32 Global Protein Therapeutics Market Outlook, By Cardiovascular Diseases (2022-2030) ($MN)
33 Global Protein Therapeutics Market Outlook, By Neurological Disorders (2022-2030) ($MN)
34 Global Protein Therapeutics Market Outlook, By Other Applications (2022-2030) ($MN)
35 Global Protein Therapeutics Market Outlook, By End User (2022-2030) ($MN)
36 Global Protein Therapeutics Market Outlook, By Hospitals (2022-2030) ($MN)
37 Global Protein Therapeutics Market Outlook, By Pharmaceutical Companies (2022-2030) ($MN)
38 Global Protein Therapeutics Market Outlook, By Research Institutions (2022-2030) ($MN)
39 Global Protein Therapeutics Market Outlook, By Biotechnology Firms (2022-2030) ($MN)
40 Global Protein Therapeutics Market Outlook, By Other End Users (2022-2030) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
List of Figures
RESEARCH METHODOLOGY
We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.
WHY CHOOSE US ?
Assured Quality
Best in class reports with high standard of research integrity
24X7 Research Support
Continuous support to ensure the best customer experience.
Free Customization
Adding more values to your product of interest.
Safe & Secure Access
Providing a secured environment for all online transactions.
Trusted by 600+ Brands
Serving the most reputed brands across the world.
